02206nas a2200289 4500000000100000008004100001260001200042653002300054653001200077653002100089653001500110653002100125653001100146653001100157100001100168700001500179700001700194700001400211700001700225700001400242245008000256856009000336300000900426490000700435520146000442022001401902 2023 d c11/202310aImmunopathogenesis10aleprosy10aLeprosy reaction10atratamento10anerve impairment10atype 110atype 21 aDewi D1 aDjatmiko C1 aRachmawati I1 aArkania N1 aWiliantari N1 aNadhira F00aImmunopathogenesis of Type 1 and Type 2 Leprosy Reaction: An Update Review. uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733783/pdf/cureus-0015-00000049155.pdf a1-140 v153 a
Leprosy reactions are acute exacerbations of the signs and symptoms of leprosy occurring during the natural course of the disease and during or after treatment. Left untreated or improperly managed, reactions can lead to severe nerve function impairment and subsequently to disabilities. In the present context of leprosy eradication efforts, leprosy reactions continue to pose a significant and enduring challenge. Type 1 leprosy reaction and type 2 leprosy reaction are substantial contributors to nerve impairment and the subsequent development of enduring impairments. The study of immunopathogenesis of leprosy reactions has emerged as a significant area of research due to its potential to identify critical targets for the early detection and management of these episodes. This study aims to reveal the pathogenesis of type 1 and 2 leprosy reactions so that they can form the basis for their treatment. The study used scientific journals from reputable platforms such as PubMed, Scopus, and Google Scholar to evaluate the pathogenesis of leprosy reaction type 1 and 2 in leprosy patients. This review indicates that the progression of leprosy nerve damage and sensitivity to reactions may be predicted using genetic and serum markers in the human host. A more profound comprehension of the molecular processes underlying leprosy reactions may offer a logical plan for early detection and leprosy reaction complication prevention.
a2168-8184